Market Scope

Market Research Future (MRFR) believes that the bile duct cancer market will potentially capture an approximate growth rate of 9.2% during the evaluation period, which is between 2022 and 2030. 

Growth Boosters and Challenges

The bile duct cancer industry is thriving on the back of surging burden of the condition worldwide and the increasing efforts to bring down its prevalence. Technological advances to improve the quality of the treatment in line with the growth of spending on the healthcare industry should further work in favor of the bile duct cancer market. Additionally, pharmaceutical firms’ rising focus on research and development of novel therapy to treat bile duct cancer should also benefit the global market. 

Governments are taking up initiatives to boost financial assistance to facilitate upgradations in the pharmaceutical sector, which could ensure sustained growth in the coming years. Rising prominence of infections like liver fluke will boost the demand for bile duct cancer treatment while the constant exposure to toxic chemicals among industrial workers will facilitate market growth. 

Top Contenders

The players spearheading the market for bile duct cancer include Bristol-Myers Squibb Company (U.S.), Fresenius Kabi AG (Europe), Pfizer Inc. (U.S.), Eli Lilly and Company. (U.S.), Sanofi (Europe), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), F. Hoffmann-La Roche Ltd (Europe), and more.

Market Segmentation

To offer a comprehensive framework, MRFR has segmented the Bile Duct Cancer Market size into types, diagnosis, treatment, and end users.

The different types of bile duct cancer are extrahepatic, intrahepatic, and more.

Diagnosis-wise, the market segments include surgery, abdominal imaging, blood tests, and others. The diagnosis-based segments are abdominal imaging, which in turn is split into magnetic resonance cholangiopancreatography (MRCP), percutaneous transhepatic cholangiography (PTC), endoscopic retrograde cholangiopancreatography (ERCP), and more.

The various treatment lines for bile duct cancer available in the market are radiotherapy, chemotherapy, and others. The chemotherapy-wise major segments can be gemcitabine, cisplatin, 5-fluorouracil, and others. Factors including rising number of chemotherapeutics agents available for treating bile ducts cancer and the surge in research work to improve the quality of chemotherapy via clinical trials should help the segment escalate rapidly in the years to come.

Significant end users in the global market are research organizations, academic institutes, hospital &clinics, and others.

Regional Status 

The major markets for bile ducts cancer include Europe, Asia Pacific or APAC, the Americas, as well as the MEA or Middle East & Africa.

The Americas has been at the forefront of the global industry and will remain profitable throughout the evaluation period. The presence of a modern healthcare infrastructure and the fact that most of the firms in the region indulge in research collaborations as well as joint ventures favors the market. The cases of bile duct cancer have been escalating rapidly in the region, giving way to a massive number of research activities by government and non-government firms. Increase in approval processes, surge in awareness campaigns, and the rise in public and private spending also ensures robust market growth in the region. Moreover, with the U.S. emerging as the leading consumer for angiography equipment, the bile duct cancer market in the region should maintain its winning streak all throughout the given period.

Europe is the second highest gainer in the global market and will continue thriving rapidly in the next few years, thanks to the financial aid by the government in terms of research and development activities. Growing participation of various universities, and academic and research institutes could further strengthen the market position. Substantial investments in exhaustive R&D activities have also led to significant market growth, while supportive government policies add to the revenue generation in the region.

Asia Pacific will remain a highly lucrative market from 2020 to 2027, given that bile duct cancer is rapidly spreading across a number of countries like Thailand and Indonesia. The region is a prominent consumer of raw fish, which fosters the chances of developing liver fluke infections that results in bile duct cancer. Surge in industrialization also enhances the size of the bile duct cancer market in the region, since exposure to toxic chemicals puts the workers in Japan, India and China in the way of harm.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

United States of America